Overview of cell-based tools for pre-clinical assessment of immunogenicity of biotherapeutics

Journal of Immunotoxicology

Volumn 3, Issue 3, 2006, Pages 131-136

  Kropshofer, Harald ^a   Singer, Thomas ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Biotherapeutic drugs; Dendritic cell; Immunogenicity; Pre clinical risk assessment; T cell activation

Indexed keywords

CD4 ANTIGEN; DRUG ANTIBODY; EPITOPE; NEUTRALIZING ANTIBODY; PEPTIDE LIBRARY;

ALGORITHM; ANTIBODY RESPONSE; COMPUTER MODEL; CONFERENCE PAPER; DENDRITIC CELL; HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNOGENICITY; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING; T LYMPHOCYTE ACTIVATION; VIRAL GENE THERAPY;

EID: 33747628127     PISSN: 1547691X     EISSN: 1547691X     Source Type: Journal    
DOI: 10.1080/15476910600845625     Document Type: Conference Paper

References (12)

1. Barbosa, M. D., Vielmetter, J., Chu, S., Smith, D. D., and Jacinto, J. 2006. Clinical link between MHC Class II haplotype and interferon-β (IFN-β) immunogenicity. Clin. Immunol. 118:42-50.
2. Bian, H., and Hammer, J. 2004. Discovery of promiscuous HLA-II-restricted T cell epitopes with TEPITOPE. Methods 34:468-475.
3. Clark, M. 2000. Antibody humanization: A case of the 'Emperor's newclothes'? Immunol. Today 21:397-402.
4. De Groot, A. S., Knopf, P. M., Foti, S., and Martin, W. 2005. De-immunization of therapeutic proteins by T-cell epitope modification. Devel. Biol. 122:171-194.
5. Desmet, J., Meersseman, G., Boutonnet, N., Pletinckx, J., de Clercq, K., Debulpaep, M., Braeckman, T., and Lasters, I. 2005. Anchor profiles of HLA-specific peptides: Analysis by a novel affinity scoring method and experimental validation. Proteins 58:53-69.
6. Haselbeck, A. 2003. Epoetins: Differences and their relevance to immunogenicity. Curr. Med. Res. Opin. 19:430-432.
7. Hermeling, S., Aranha, L., Damen, J. M. A., Slijper, M., Schellekens, H., Crommelin, D. J. A., and Jiskoot, W. 2005. Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b. Pharm. Res. 22:1997-2006.
8. Koren, E., Zuckerman, L. A., and Mire-Sluis, A. R. 2002. Immune responses to therapeutic proteins in humans-clinical significance, assessment, and prediction. Curr. Pharm. Biotech. 3:349-360.
9. Kropshofer, H., and Spindeldreher, S. 2005. Naturally processed self-peptides of MHC molecules. In: Antigen Presenting Cells, ed., pp. 159-198. Weinheim: Wiley-VCH.
10. Tangri, S., Mothe, B. R., Eisenbraun, J., Sidney, J., Southwood, S., Briggs, K., Zinckgraf, J., Bilsel, P., Newman, M., Chesnut, R., LiCalsi, C., and Sette, A. 2005. Rationally engineered therapeutic proteins with reduced immunogenicity. J. Immunol. 174:3187-3196.
11. Vogt, A. B., Ploix, C., and Kropshofer, H. 2005. Antigen processing for MHC Class II. In: Antigen Presenting Cells, ed. pp. 89-128. Weinheim: Wiley-VCH.
12. + T-cell epitope in human IFN-β does not result in an in vivo response directed at the subdominant epitope. J. Immunol. 172:6658-6665.